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Abstract Autoantibodies termed C3-nephritic factor
(C3NeF), which stabilize convertases of the alternative com-
plement pathway, often stimulate autoinflammatory diseases.
However, knowledge about analogous autoantibodies acting
on the classical pathway (C4NeF) is limited to a few reports,
which indicate association with kidney dysfunction, systemic
lupus erythematous, and infections. C4NeF may appear inde-
pendently from C3NeF, but the lack of a routine diagnostic
method predisposes C4NeF for being an underestimated player
in autoinflammatory episodes. We tested the activity of classi-
cal convertases directly in serum/plasma to screen samples
from 13 patients with C3 glomerulopathies and identified one
patient showing significantly prolonged half-life of these en-
zymes. Observed effect was reproduced by immunoglobulins
purified from patient’s plasma and additionally confirmed
on classical convertase built from purified components.
Isolated immunoglobulins protected classical convertases
from both spontaneous and inhibitor-driven decay but
not from C4b proteolysis. The patient had a decreased
serum level of C3, elevated sC5b-9, and normal concen-
trations of factor B and C4. Neither C3NeF nor other
autoantibodies directed against alternative pathway pro-
teins (factor H, factor B, factor I, C3, and properdin)
were found. Genetic analysis showed no mutations in
C3, CFB, CFH, CFI, MCP, THBD, and DGKE genes.
Renal biopsy revealed a membranoproliferative pattern
with intense C3 deposits. Our results underline the im-
portance of C4NeF as an independent pathogenic factor
and a need for the implementation of routine examina-
tion of classical convertase activity. Proposed method
may enable robust inspection of such atypical cases.
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Three different routes may drive the complement system, an
important constituent of innate immunity: the classical, lectin,
and alternative pathways. Whereas the first two pathways are
initiated by certain stimuli such as antibodies bound to the cell
surface or the presence of pathogen-specific sugar moieties,
the alternative pathway is constantly active at a low level and
its further propagation depends on the lack of restriction by
endogenous complement inhibitors [1]. The alternative or
classical/lectin pathway complement convertases are the ele-
ments of the cascade, which are particularly controlled by
complement inhibitors. Otherwise, convertases produce opso-
nins, anaphylatoxins, and initiate the formation of the mem-
brane attack complex aimed to lyse target cells [2]. Under
physiological conditions, the maximal activity of convertases
is reached relatively quickly after pathway initiation (seconds
or minutes, depending on complement availability, as shown
in [3]) and after this time their activity decreases due to spon-
taneous and inhibitor-driven decay as well as proteolysis of
C3b and C4b components by factor I [4]. Diverse modes of
c omp l emen t a c t i v a t i o n d e t e rm in e t h e r i s k o f
autoinflammatory diseases resulting from misguided or un-
controlled complement attack. A loss of regulation of the al-
ternative pathway is sufficient for pathologic events whereas
in the case of the classical and lectin pathways, an analogous
condition must be accompanied with a pathway-specific stim-
ulus present on self cells. Indeed, mutations in alternative
pathway components are well-known etiologic/risk factors
for diseases such as C3 glomerulopathies (C3G) [5] or atypi-
cal hemolytic uremic syndrome (aHUS), which manifest al-
ready at a very young age [6]. Another condition, which leads
to the unrestricted activity of alternative convertases, is the
presence of autoantibodies termed C3NeF. C3NeF binds
neoepitopes formed upon the assembly of the convertase
and stabilizes it, result ing in consumption of C3
(hypocomplementemia) and amplification of downstream
events in the complement cascade. Occurrence of C3NeF is
reported in almost all patients with dense deposit disease and
in half of the patients with C3GN [7]. Interestingly, this auto-
antibody was also found in an individual showing no disease
symptoms [8] and its presence in some C3GN patients did not
cause hypocomplementemia [9], but, on the other hand, the
same study reported C3NeF-positive C3GN in the absence of
other known disease-causing agents [9]. In contrast to the
deregulation of alternative pathway convertases by either mu-
tations in pivotal pathway components or autoantibodies,
similar phenomena for the classical pathway convertases are
poorly described, with not a single report about a gain-of-
function mutation and only a few reports about C4NeF (anal-
ogous to C3NeF). Incidence of C4NeF was briefly reviewed
in [10] and reported in postinfectious glomerulonephritis [11,
12], membranoproliferative glomerulonephritis [13], systemic
lupus erythematous [14], and recently in a patient with sepsis
caused by Neisseria meningitidis [15]. There are two reports
on C4NeF occurrence in large cohorts with renal diseases,
which show C4NeF in 19 out of 100 patients [13] and 19
out of 197 patients [16], respectively. Interestingly, the per-
centage of patients double-positive for C3NeF and C4NeF
was 52 [13] and 10 % [16] depending on cohort, showing that
these two kinds of activities may appear independently of each
other. Also, there are reports showing that C4NeF may stabi-
lize not only C3 classical convertase but also C5 classical
convertase [15, 17]. There is no routine diagnostic procedure
for C4NeF determination. Available experimental methods
are based on multistep hemolytic assays performed on sheep
erythrocytes coated with purified components of classical
convertases (EAC142 or EAC1423) [13, 15] or precipitation
of stabilized fluid-phase C4b2a complexes followed by detec-
tion by sandwich ELISA [18]. An obvious limitation of de-
tection systems based on purified complement components is
elimination of interactions with other components from autol-
ogous serum, which are normally present under physiological
conditions and may influence convertase formation and sta-
bility. On the other hand, detection of stabilized, fluid-phase
classical convertase precipitated from patient serum does not
give any information about enzymatic activity. We have de-
signed a new method for assessment of convertase activity
directly in patient’s serum or plasma, which makes use of
C5 blockers: OmCI or eculizumab [19]. Thereafter, we
showed that our approach enables proper detection of clinical
samples with altered function of alternative convertases
caused by either autoantibodies (C3NeF, anti-factor H) or mu-
tations in complement proteins (C3, factor B) [19]. Herein, we
report the usage of this method for screening for abnormally
prolonged activity of classical convertases and, by doing so,
identification of C4NeF activity in a patient with C3 glomer-
ulonephritis of previously unknown etiology. Further analysis
revealed that the specific activity responsible for the pheno-
type was conferred in the Ig fraction isolated from plasma.
Materials and Methods
Reagents, Sera and Patient Material
Normal human serum (NHS) was prepared from blood of
healthy volunteers after written informed consent had been
obtained and according to the permit by the ethics committee
in Lund (permit number 2013/846). Blood was collected and
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kept at room temperature for 30 min to coagulate, then on ice
for another 60 min followed by centrifugation for 7 min at
700×g. The serum fraction was collected, centrifuged again
to remove residual erythrocytes, aliquoted, and stored at
−80 °C until use. Thirteen patients with biopsy-proven C3
glomerulopathy (3 with dense deposit disease and 10 with
C3 glomerulonephritis) diagnosed between 1970 and 2015
were selected based on the availability of sera and/or plasma
samples to complete all assays, as well as histopathologic data
(light microscopy, immunofluorescence, and electron micros-
copy) to review the pathologic diagnosis. Serum and EDTA-
plasma samples were obtained under standard conditions with
informed consent and with the approval of Hospital
Universitario La Paz; blood was collected into plain tubes,
allowed to clot at room temperature, and centrifuged for
10 min at 4 °C. After that, serum and plasma were collected,
aliquoted, and kept frozen at −80 °C until use. List of the
patients with indicated diagnoses and complement-related pa-
rameters is given in Table 1. Purified human C2, C3, C4, C4b,
FB, FD, properdin, FI, and FH were purchased from Comp
Tech. OmCI, a recombinant inhibitor of C5 cleavage, was
expressed and purified as described in [19]. Guinea pig serum
was purchased from Harlan Laboratories. Human sera deplet-
ed from C3 and/or C5 as well as mouse anti- C4d antibody
(A253) were purchased from Quidel. Soluble CD55 (DAF)
was produced recombinantly in eukaryotic system as de-
scribed [20]. Factor I (FI) [21] and C4b-binding protein
(C4BP) [22] used in C4b degradation assay were purified
from human plasma. Monoclonal antibody MK104 against
C4BP was homemade and purified using protein A affinity
chromatography as described [23].
Genotyping and Mutation Screening
Genomic DNA was extracted from peripheral blood using
standard procedures. Exons of the CFH, MCP, CFI, C3,
CFB, THBD, and DGKE genes were amplified from genomic
DNA using primers derived from the intronic sequences as
described [24–26]. Automatic sequencing was performed in
an ABI3730 sequencer using a dye terminator cycle sequenc-
ing kit (Applied Biosystems). The analysis of the DCFHR3-
CFHR1 polymorphism and genomic rearrangements in the
CFH-CFHRs region were assessed by multiplex ligation-
dependent probe amplification (MLPA) with the P236 A1
ARMD mix 1 (MRC-Holland, Amsterdam, Netherlands).
Properdin, C3, C4, FB, C5, and sC5b-9 Quantification
Properdin levels were measured by ELISA as described in
[27]. Serum levels of C3 and C4 were measured by nephe-
lometry (Siemens Healthcare, Marburg, Germany). Serum FB
levels were determined by ELISA using 100 ng/well of pro-
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human FB antibody (Calbiochem, #341272) as capture anti-
body and a monoclonal mouse anti-human Bb (A227, Quidel,
San Diego, CA) as the detection antibody. C5 serum levels
were determined following an ELISA described in [28].
Circulating sC5b-9 was analyzed using a commercially avail-
able assay (A029, Quidel).
C3NeF Detection by ELISA
C3NeF detection in serum samples was performed as previ-
ously described [29] with several modifications. Briefly, two
ELISA assays were performed: COSP (to measure the
stabilizing-capacity of serum C3NeF) and COIgG (to detect
the binding of C3NeF to the AP C3 convertase). In both as-
says, ELISA plates (Medisorp, Nunc) were coated with C3b
(1 μg/ml in PBS, overnight, 4 °C). Convertase was formed by
adding 50 μl test serum (1/50 in assay buffer), immediately
followed by 50 μl of a mixture comprising FB (1 μg/ml) and
FD (0.2μg/ml) with properdin (0.5μg/ml) in assay buffer. For
COSP, a 1/500 dilution of a monoclonal anti-human Bb frag-
ment (Quidel, #A227) was used to detect the presence of re-
sidual Bb fragments on the stabilized C3bBbP complex. A
peroxidase-conjugated goat anti-mouse IgG (H + L)
(Invitrogen) diluted 1:1000 was used as secondary antibody,
and the reaction was developed with OPD. The COIgG assay
was performed as described in [29] except that the assay buff-
er contained 1 mM of MgCl2 instead of NiSO4 in order to
reduce background.
Antibody Binding to Immobilized C3, FB, FI, FH,
and Properdin
ELISA plates were coated with 100 ng/well of purified C3,
FB, FI, FH, or properdin. Plates were blocked with PBS-BSA
3 % in case of FB and properdin, and with PBS-BSA 0.1 % in
FI and C3. Serum samples were diluted in PBS-BSA 0.1 %,
and binding of autoantibodies was detected with polyclonal
anti-human IgG-HRP conjugated antibody (Jackson
Immunoresearch) in ABTS substrate, as described in [30].
Factor H autoantibodies were analyzed as previously de-
scribed in [31].
Purification of Whole Ig Fraction
Whole Ig fraction was purified from 1 ml of EDTA-plasma of
patient seven and 1 ml of normal human serum pooled from
13 healthy volunteers, by affinity chromatography on 5 ml
protein A and protein G Sepharose Hi-Trap columns (GE
Healthcare). Samples were loaded, the unbound fraction was
washed with PBS buffer and then Ig eluted with 0.1 M
glycine-HCl buffer pH 2.5. Fractions containing proteins were
immediately neutralized with 1/10 volume of 1 M Tris-HCl
pH 8.0, dialyzed against PBS, and concentrated using 10 kDa
molecular weight cut-off value device (Vivaspin).
Functional Assays for Activity of Classical Convertases
Activity of classical complement convertases was tested either
in full serum/plasma or in a setting with whole Ig fraction
purified from patients’ blood, as described in [19] and [3],
respectively. Additional analysis testing the stability of
convertases built up from purified components was performed
on sheep erythrocytes (Hatunalab AB or BioMaxima) sensi-
tized with anti-sheep erythrocyte antibody Amboceptor
(Behring). Erythrocytes were prepared as described [3]
and then incubated with 2.5 μg/ml of C1 and C4 for
10 min at 30 °C in DGVB veronal buffer. Afterwards,
2.5 μg/ml of C2 was added with various dilutions of whole
Ig fraction isolated from patient seven or normal human
serum. Incubation was performed for up to 90 min, and
reaction was stopped at chosen time points. Erythrocytes
were washed with ice-cold 40 mM EDTA-GVB buffer and
centrifuged for 1 min at 1000×g. Pellets were resuspended
in 50 μl of fresh 40 mM EDTA-GVB containing guinea pig
serum diluted 1:40 and overlaid with additional 50 μl of
DGVB. After 20 min of incubation at 37 °C, cells were
centrifuged. Supernatant was collected and placed in a
flat-bottom plate, and absorbance at 405 nm was measured
with a microplate reader.
Determination of C4d Content
C4d measurement aimed to determine the rate of C4b inacti-
vation by FI-mediated cleavage was performed by sandwich
ELISA assay using anti-neoepitope C4d antibodies raised in-
house, as described in [32]. Samples containing 5 μg/ml C4b
(Comp Tech) and 10 μg/ml of C4BP and FI and alternatively
control or patient’s whole Ig fraction or 500 μg/ml of rabbit-
anti C4c antibody (Dako, #Q0369) were incubated for 1 h and
then loaded onto ELISA plate.
Visualization of C4b Cleavage Pattern
Thirty microgram per milliliter of C4b (Comp Tech) and
100 μg/ml of C4BP were mixed and optionally supplied with
10 μg/ml of FI and 500 μg/ml of rabbit-anti C4c antibody.
Mixture was incubated overnight at 37 °C, and then 3x
Laemmli buffer was added and after boiling for 5 min samples
were separated by 10 % SDS-PAGE. After electrophoresis
gel was blotted onto PVDF membrane and signal from C4
fragments was developed with mixture of 1:1000 mouse
anti-C4d (clone LP69, Abcam) and 1:1000 of goat anti-
C4 (Comp Tech, #A205), followed by mixture of goat
anti-rabbit and anti-mouse HRP-conjugated Abs (Dako,
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#P0448 and #P0447). Western blot was visualized with
DAB, as described in [33].
Results
Screening of Serum/Plasma Samples for Prolonged
Activity of Classical Complement Convertases
The plasma/serum samples of 13 patients with confirmed C3
glomerulopathies (listed in Table 1) were included in a screen-
ing assay testing the activity of classical convertases over time
(Fig. 1). Since the patients presented with different degrees of
hypocomplementemia, all samples were diluted to 1 % final
concentration and then mixed with an equal amount of normal
human serum (NHS). This step enabled normalization of the
readout but the addition of an extra 1 % of NHS did not affect
convertase activity curves, as evidenced by the lack of differ-
ences between 1 and 2 % NHS samples (Fig. 1). However, it
allowed the detection of factors present in individual serum/
plasma samples which caused prolongation of classical
convertase activity. In the case of sample 7, convertase activity
was significantly elevated from the time point of 5 min
(p<0.01 according to two-way ANOVA, comparing to 1 %
NHS) and continued to time points of 10 and 20 min
(p<0.001). The activity of other clinical samples did not differ
significantly from NHS controls (Supplementary Fig. 1).
Stabilization of the Classical C3/C5 Convertase Activity Is
Supported by the Ig Fraction Isolated from the Patient’s
Plasma
We investigated whether the effect on classical convertase
exerted by plasma from patient seven could be reproduced
by addition of the Ig fraction only to 1 % NHS. Total Ig was
purified from 1 ml of the patient’s plasma by protein A/G
affinity chromatography. The obtained preparation was con-
centrated to the initial plasma volume and used in an experi-
ment similar to that presented in Fig. 1. Results showed no
significant differences between NHS supplemented either
with 1 % patient’s serum or an equal volume of purified Ig
fraction (Supplementary Fig. 2). To confirm whether the
prolonged stability of the classical complement convertase in
the plasma of patient seven is attributed to C4NeF activity, we
investigated whether purified antibodies from patient seven
stabilize both C3 and C5 classical convertases. To answer this
question, we applied another assay described in [3], which
operates in C3- or C5-depleted serum. These sera support
the formation of C3 and C5 classical convertases, respectively,
on Ab-sensitized sheep erythrocytes. Addition of Ig purified
from patient seven resulted in significantly prolonged activity
of both classical convertases when compared to control Ig
purified from NHS (Fig. 2).
C4NeF from Patient Seven Prevents Both Spontaneous
and Inhibitor-Driven Convertase Decay but Not Factor
I-Mediated Proteolysis of C4b
Further experiments aimed to identify the mechanism, by
which C4NeF isolated from patient seven stabilizes classical
convertases. First, we checked whether putative binding of
autoantibodies to classical convertases protects them from
spontaneous decay. Convertases were built up by deposition
of purified C1 and C4 onto the surface of sensitized sheep
erythrocytes followed by the addition of purified C2 together
with Ig isolated from the patient or from NHS. Additional
controls were aimed to test convertase decay, when either no
Ig or a soluble version of complement inhibitor CD55 (CD55-
Fc) were added. Erythrocytes incubated without C2 served as
negative control. The addition of Ig isolated fromNHS did not
affect the convertase activity profile in contrast to the addition
of Ig isolated from patient seven, which stabilized convertase
activity (Fig. 3a). Addition of CD55-Fc resulted in diminished
convertase activity at the first time point tested and a subse-
quent, rapid drop of activity down to the level of the negative
control, as expected. Thereafter, we tested whether C4NeF
from patient seven is capable of counteracting inhibitors
which accelerate convertase decay, using the inhibitor CD55
as a model. Addition of C4NeF could not rescue the initial
drop of convertase activity measured at the first time point, but
in contrast to control Ig it efficiently prevented the accelerated
Fig. 1 Screening of clinical serum and plasma samples for prolonged
activity of classical convertases. Thirteen samples collected from the
patients with C3 glomerulopathies were diluted to final concentration of
1 %, mixed with equal volume of NHS and inhibitor of C5 cleavage was
added. Samples were incubated with sensitized sheep erythrocytes for
indicated time period and then washed and incubated with guinea pig
serum diluted in 40 mM EDTA-GVB buffer, which disabled de novo
convertase formation but allowed development of lytic sites only from
pre-existing convertases. Percentage of lysis measured at 405 nm was
referred to the equal amount of sensitized erythrocytes lysed with equal
volume of water. Data were collected from three independent
experiments, statistical significance was assessed by two-way ANOVA
at **p< 0.01 and ***p < 0.001, respectively. Only four clinical samples
including #7 were shown for better clarity of the graph but none of the
clinical samples but #7 showed statistically significant differences when
compared to NHS controls. Graph showing all 13 patients versus healthy
controls (normal human serum) is presented in Supplementary Fig. 1
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drop in activity at further time points (Fig. 3b). Next, we
checked whether C4NeF from patient seven also protected
convertases from the FI-mediated cleavage of C4b. For exam-
ple, antibodies targeting C4 may hinder binding sites for FI
and/or its cofactors, and by doing so, disable C4b cleavage, as
we showed in Fig. 3c for anti-C4c antibodies. Our preliminary
experiment, in which we tested patient’s and control Igs in the
same setting, did not show differences in C4b cleavage (not
shown). However, reliable visualization of C4NeF influence
on C4b cleavage with this method would demand substantial
quantities of isolated C4NeF, which we could not supply.
Therefore, we chose another technique based on the quantifi-
cation of the C4d cleavage product by a highly sensitive sand-
wich ELISA [32], which allowed minimizing the amount of
required C4b and so enabled the testing of a fair molar excess
of antibodies over C4b. Surprisingly, there was a trend to-
ward a more pronounced generation of C4d when the pa-
tient’s Ig were present but these differences did not reach
statistical significance at any of the Ig concentrations tested
(Fig. 3d). Nonetheless, based on these results, we conclude
that the C4NeF activity of Ig isolated from patient seven
could not be attributed to an interference with proteolytic
inactivation of C4b. Using analogous method and
function-blocking antibodies against FI and C4BP, we tried
to assess the importance of convertase decay-acceleration
versus FI-mediated proteolysis of C4b for overall
convertase activity. Unfortunately, addition of purified
IgG fraction isolated from the patients diminished trustful
range of readout and prevented from reliable conclusions
(not shown). Nonetheless, in previous publication, we
showed that blocking of FI function does not affect stabil-
ity of classical convertases as much as blocking of C4BP
[3] and extrapolation of these findings seems to be appli-
cable in the current case.
Clinical Manifestation of Disease in Patient Seven
In order to analyze the case of patient seven, the only individ-
ual whose sample was yielding positive result in our C4NeF
screening assay, we investigated related clinical data. Hewas a
55-year-old man referred to a hospital for a nephrotic syn-
drome study, on the basis of a casual finding of high protein-
uria in a periodic analytical control. There was no familial
history of renal disease, but he and his father and brothers
are diagnosed with dyslipidemia and systemic arterial hyper-
tension. At the time of the study, the patient presented normal
blood cell counts, decreased total serum protein levels (48 mg/
mL), as well as low serum albumin (2.8 mg/mL). IgG count
was also low (4.23 mg/mL, normal range 7.25–19), but IgA
and IgMwere normal (1.53 mg/mL, normal range 0.5–3.4 and
0.83 mg/mL, normal range 0.45–2.8, respectively). Serum
creatinine and urea were at the upper limit of normal range
(12 and 400 mg/L). Hematuria and proteinuria (2 g/L) were
found, reaching up to a protein loss of 16 g in 24-h urine
analysis. Complement C3 serum levels were decreased, but
C4 and C1q were within their normal ranges and factor B (FB)
was even higher than normal range. A test for anti-nuclear
autoantibodies was negative.
At this time, renal biopsy was performed. Of the 36 glo-
meruli obtained in the biopsy, three were totally sclerosed.
Fig. 2 Influence of patient’s and control Ig on stability of C3 and C5
classical convertases. In order to assess the influence of total Ig fraction
purified from patient seven plasma on classical C3 and C5 convertase, Ig
preparations were mixed with 1 % C3-depleted or C5-depleted serum,
respectively, and incubated with sensitized sheep erythrocytes for an
indicated period of time. Samples were wzashed and incubated with
guinea pig serum diluted in 40 mM EDTA-GVB buffer, which disabled
de novo convertase formation but allowed development of lytic sites only
from pre-existing convertases. Percentage of lysis measured at 405 nm
was referred to the equal amount of sensitized erythrocytes lysed with
equal volume of water. Ig preparation from NHS was used as a negative
control. Data were collected from three independent experiments;
statistical significance was assessed by two-way ANOVA
522 J Clin Immunol (2016) 36:517–527
Extracapillary proliferation was absent and sporadic leukocyt-
ic infiltrations were observed. Biopsy showed diffuse in-
creased capillary walls, with split basal membrane and irreg-
ular subendothelial deposits. On direct immunofluorescence,
intense clumpy C3 deposits on glomerular capillaries and
mesangium were observed. IgG deposits showed a similar
pattern but with lower intensity. Capillary and mesangial
IgM, C1q, and C4d deposits were also evidenced, and kappa
and lambda chains to a lesser extent. A complement related-
glomerular disease was suspected, because of the
membranoproliferative pattern with the intense C3 deposits
observed in the biopsy and the persistently decreased C3 se-
rum levels. Three months after diagnosis, renal function was
progressively worsening, with serum creatinine of 13.7 mg/L
and persistent nephritic syndrome; the patient was referred to
perform additional, detailed complement studies. The
decreased levels of circulating complement C3 and properdin
suggested alternative pathway activation, but FB was not di-
minished. The patient had a high C5 convertase activity,
which was reflected by a C5 concentration within lower levels
of normal range and elevated sC5b-9. The patient was
screened for the presence of C3NeF and other autoantibodies
directed to alternative pathway proteins (FH, FB, FI, C3, and
properdin), and all resulted negative. In the genetic analysis,
no mutations were identified in C3, CFB, CFH, CFI, MCP,
THBD, and DGKE genes.
Technical Performance of the Assay
We propose that our assay may be used as an efficient screen-
ing method for presence of factors interfering with activity of
classical convertases. In order to evaluate the reproducibility
Fig. 3 Mechanism of convertase stabilization by C4NeF isolated from
patient seven. a Spontaneous decay of classical C3 convertase assembled
from purified components. Sensitized erythrocytes were coated with C1
and C4. Addition of C2 initiated the process of convertase formation.
Convertase activity was assessed at indicated time points in the same
manner, as described in Figs. 1 and 2. b The same experiment as in a
but with CD55-Fc added together with C2. c Representative blot of the
C4b degradation pattern (C4b, factor I, and C4BP present) and
comparison to negative control with no factor I added and sample, in
which C4b cleavage was inhibited by excessive anti-C4c antibody. d
Quantification of C4d produced upon C4b degradation in the presence
of Igs isolated from patient seven or from NHS. When anti-C4c
antibodies were tested in the same experiments, C4d readout was below
the lower level of detection and therefore is not shown. All graphs show
data collected from at least 3 independent experiments and statistical
significance was assessed with two-way ANOVA assay at *p < 0.05,
**p< 0.0,1 and ***p< 0.001
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of the assay, we assessed intra- and inter-assay coefficient of
variation (CV). Such analyses were performed for 1 % normal
human serum sample expected to reflect normal profile of
classical convertases activity over the time. In order to addi-
tionally validate the method and to visualize the effect of
negative and positive controls, we also analyzed 1 % serum
supplemented with 300 nM of soluble CD55-Fc (modeling
the influence of convertase inhibitors and resulting in di-
minished convertase activity) and serum supplemented
with 300 nM of MK104 (monoclonal antibody, which
blocks function of C4BP, the main fluid-phase inhibitor
of classical convertases [34]) resembling the effect of
C4NeF. Intra-assay CV was performed with eight repeti-
tions per experiment, which represented whole column of
standard, 96-well microplate whereas inter-assay CV was
calculated from three independent experiments (Fig. 4).
Intra-assay CV values did not exceed 8 % for any of time
points. Average inter-assay CV values obtained for control
and MK104 samples were 8.8 and 12.6 %, respectively.
However, higher CV values were obtained only for sam-
ples representing low readout. This was evident for CD55-
Fc samples, which generally achieved very low readouts
but variability at such close-to-background level within
separate experiments resulted in substantial CV values.
Nonetheless, statistical significance for difference between
CD55-Fc and control samples was achieved and we as-
sume that our method offers a good chance to distinguish
samples with hyperact ive class ical conver tases .
Importantly, experiments on intra- and inter-assay CV
were performed on separate batches of erythrocytes from
two different vendors and obtaining of similar patterns of
convertase activity additionally ensure the reproducibility
of the method.
Discussion
Convertases are central enzymatic complexes in the comple-
ment system, as they catalyze C3 and C5 activation, produce
anaphylatoxins, and initiate the terminal lytic pathway.
Therefore, it is not surprising that the majority of endogenous
inhibitors including factor H, factor I, C4BP, CR1, CD46, and
CD55 control convertase activity [35, 36] and that pushing the
balance between convertase activation and inhibition by either
mutations or autoantibodies results in autoinflammatory
events. Certain complement inhibitors like factor H possess
Fig. 4 Reproducibility of the assay testing the activity of classical
complement convertases. Intra- (left panel) and inter- (right panel) assay
coefficient of variation were assessed for control sample (1 % NHS),
positive control sample (1 % NHS supplemented with 300 nM
MK104), and negative control sample (1 % NHS supplemented with
300 nM CD55-Fc). CV values for each time point are given in percent
under the graphs, and average values are indicated with gray font.
Statistical significance was assessed with two-way ANOVA assay at
**p< 0.01 and ***p < 0.001
Fig. 5 Algorithm for selection of patients with hyperactive classical
convertases. APAb antibodies against alternative pathway components
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multiple polymorphic variants but, paradoxically, different
mutations causing redundant phenotypes in terms of comple-
ment regulatory function do not predispose to the same dis-
ease [37]. This is partially explained by interactions with car-
bohydrates, which form distinct patterns depending on their
locations, e.g., the brain, eye, or kidney [38]. However, the
matter seems to be more complex and one of the acknowl-
edged theories assumes the need of multiple hits by gain-of-
function mutations in complement activators, loss-of-function
mutations in complement inhibitors, and/or presence of auto-
antibodies for complete penetrance of diseases such as aHUS
[39, 40]. The kidney is the organ that is especially vulnerable
to complement-mediated damage, as on the one hand it filters
substantial amount of blood under high pressure and on the
other hand only a single layer, flat epithelium separates the
glomerular structures from the bloodstream. It is known that
C3NeFmay be a single factor sufficient to cause dense deposit
disease or C3 glomerulonephritis. In contrast to uncontrolled
amplification of the alternative pathway as a causative factor
of autoinflammatory diseases, understanding a role for C4NeF
as a sole causative factor is more difficult. Certain hints may
be obtained from the C4NeF cases reported in SLE [14], an
autoimmune disease associated with occurrence of autoanti-
bodies targeting DNA and nuclear antigens [41]. Importantly,
the possible repertoire of targets for autoantibodies is much
broader, including membrane proteins and extracellular ma-
trix proteins [41, 42]. It is highly possible that a certain pool of
autoantibodies exists in healthy individuals but their effector
functions are blocked by anti-idiotypic antibodies [43, 44] or,
alternatively, they are present at low titers, which are not rel-
evant for massive complement activation. However, the ap-
pearance of C4NeF may disturb this equilibrium and push
complement activation to a pathological extent.
In the present work, we report a patient who presented
with hypocomplementemia, but no risk factors other than
C4NeF could be identified in spite of detailed investiga-
tion. Since this is not the only reported case showing that
C4NeF may exist independently from other factors or au-
toantibodies causing dysfunction of the complement sys-
tem [13, 15, 16], our finding emphasizes the importance
of screening for abnormal activity of classical convertases
in clinical practice. The assay we propose is superior to
other methods, as measurement of convertase activity in
serum or diluted plasma takes into account all interactions,
which may be physiologically relevant. Otherwise, putative
masking effects of other plasma proteins or possible an-
tagonisms or synergies taking place in individual samples
may be lost and the obtained results may be over- or
underestimated. Our results show that presence of C4NeF
may be the only pathogenic factor found in C3G patients.
Given that C4NeF is a rare phenomenon, it would be
useful to implement an algorithm for selection of patients,
which should be further screened for factors affecting the
activity of classical convertases. One would expect that
C4NeF should deplete available pool of C3 and C5, leave
C4 level unaffected, and increase production of sC5b-9.
On the other hand, autoantibodies targeting the alternative
complement pathway as well as mutations in complement
components would act as confounding factors for C4NeF.
Figure 5 presents a scheme of deduction aimed to select
patients with hyperactive classical convertases.
We attempted to make an insight into the nature of C4NeF
identified in patient seven and found that the Ig fraction was
capable of preventing the classical convertases from either
spontaneous or inhibitor-driven decay, as evidenced by usage
of CD55 as a model complement inhibitor with decay-
accelerating function [45]. Also, we showed that, similar to
another reported case of C4NeF [15], the stabilization effect
was exerted for both C3 and C5 classical convertases, but in
contrast to a report by Gigli et al. [12], we did not observe
protection from proteolytic inactivation of C4b. This speaks
for heterogeneity of C4NeF and suggests that these autoanti-
bodies are not monospecific but target multiple epitopes on
classical convertases, depending on the donor. Possible asso-
ciations with diseases and/or severity are still to come once
more cases of C4NeF will be functionally characterized.
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